Skip to content

Educational reference only. Not medical advice, diagnosis, or treatment, and not dosing, injection, or purchasing guidance.Medical disclaimer

Cagrilintide

The sentences below are limited to one FDA page opened for this draft.

  • FDA says cagrilintide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.
  • The same FDA page’s sentence about false research-use labels names semaglutide, tirzepatide, retatrutide, survodutide, and mazdutide. It does not name cagrilintide in that sentence. This page does not add it.

Combination products and trial names are not summarized. A standard Chinese generic name was not checked, so the Chinese title keeps the English name.

This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.

Page record

  • Type: Compound
  • Domain: peptides
  • Evidence: Not rated
  • Status: reviewed
  • Last reviewed: 2026-11-20

Sources

Referenced by

A link from another wiki page is not evidence. Facts should point at the sources above.